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Abstract
Amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, is characterized by the
progressive and selective loss of upper and lower motor neurons. Diagnosis of this disorder is based on clinical assessment,
and the average survival time is less than 3 years. Injections of IgG from ALS patients into mice are known to specifically
mark motor neurons. Moreover, IgG has been found in upper and lower motor neurons in ALS patients. These results led us
to perform a case-control study using human protein microarrays to identify the antibody profiles of serum samples from 20
ALS patients and 20 healthy controls. We demonstrated high levels of 20 IgG antibodies that distinguished the patients
from the controls. These findings suggest that a panel of antibodies may serve as a potential diagnostic biomarker for ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is a progressive neurodegenerative disorder characterized
by the loss of lower motor neurons in the brain stem and spinal
cord and upper motor neurons in the motor cortex [1]. ALS is
mainly a degenerative disorder of the motor system, although this
condition can also be accompanied by cognitive impairment. ALS
is generally a sporadic disease (SALS), but a genetic component
with an autosomal dominant inheritance has been found in 5–10%
of ALS patients [2]. In contrast to the advances made in the
genetic epidemiology of ALS, less is known about potential
environmental factors and their interaction with genetic suscep-
tibility factors [2,3].
Diagnostic criteria have been developed to improve ALS disease
classification. However, early classification is not likely to be
reliable, and most patients have a delay of nearly 1 year from the
occurrence of the first symptoms until diagnosis. Thus, additional
diagnostic tools are needed to detect ALS at earlier time points.
Molecular markers may support this effort if these markers can
segregate ALS patients from non-diseased subjects using minimally
invasive methods.
A number of studies on ALS have been carried out using post-
mortem tissues, although the target organ of ALS is not accessible
for the early detection of this disease. However, the serum may
serve as a proxy tissue to detect diagnostic biomarkers, and recent
techniques offer the possibility of detecting genomic, proteomic, or
other changes in the blood during disease progression, thereby
providing new insight into the pathological pathways of ALS [4].
The humoral immune response is increasingly a focus of ALS
research, and data suggest that multiple antibodies directed against
different motor neuron structures may play some role in the motor
neuron degeneration seen in ALS [5,6]. Furthermore, ALS
patients have been shown to mount a humoral immune response
that is harmful to motor neurons. For example, the injection of
IgG from SALS patients into mice revealed the specific labeling of
murine motor neurons [5,6].
To identify potential autoantibodies, earlier studies have
pursued hypothesis-driven approaches. In one such approach,
putative candidate autoantigens were coated onto an ELISA plate
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and incubated with patient serum samples [4,7–14]. In contrast to
such ELISAs, we set out to utilize protein microarrays, which offer
the possibility of the simultaneous analysis of 9,480 putative
autoantigens with the additional advantages of homogeneous
technical conditions and lower costs per antigen.
In the present study, we employed protein microarrays to
evaluate serum samples from 20 ALS patients and 20 non-diseased
controls, and the antibody-binding reactions were studied in order
to identify antibodies that may distinguish ALS cases from
controls.
Materials and Methods
Ethical Statement
The study was approved by the ethics committee at the Ruhr-
University Bochum, Germany and the ethics committee at the
Medical Faculty at the University of Szeged, Hungary. All
participants provided written, fully informed consent to participate
in this study. The relevant documents relating to this process are
filed at the Department of Neurology, University of Szeged,
Hungary. Only the anonymous data and materials from the
Hungarian participants (patients with ALS and controls) were
provided to the scientists carrying out the research. The data
concerning this study were stored separately from the hospital
charts of the patients.
Subjects and Samples
This ALS study had a cross-sectional design including 20 ALS
cases and 20 controls. All subjects were recruited at the
Department of Neurology, University of Szeged, Hungary.
Patients were not eligible for the study if they demonstrated
cognitive impairment (Mini-Mental State Examination score ,
27), any drug addiction, or were HIV-positive. All participants had
to be able to understand and speak the Hungarian language
fluently. ALS cases were eligible if their diagnosis was validated
according to the El Escorial revised diagnostic criteria for the
diagnosis of ALS [15]. The controls were disease-free subjects
(volunteer blood donors or other healthy volunteers) who were
unrelated to the ALS cases and who were matched to the ALS
cases by age and gender. A neurologist enrolled and diagnosed
eligible subjects according to a standardized assessment protocol,
including a neurological examination, socio-demographic ques-
tions, and disease-related questionnaires. For all ALS cases, the
severity of the disease was assessed using a revised ALS functional
rating scale (ALSFRS) and modified manual muscle testing [16].
All of the ALS cases exhibited SALS.
Blood Collection and Routine Laboratory Analysis
Venous blood samples were obtained in Hungary from an
antecubital vein through an indwelling catheter for the protein
microarray experiments and for the determination of routine
laboratory parameters. Blood samples for routine laboratory
parameters were collected in EDTA tubes containing 100 mL of
0.5% sodium disulfide solution and in 5 mL tubes for serum
preparation (KabevetteH V serum Gel S831 V, Kabe Labor-
stechnik GmbH, Nu¨mbrecht-Elsenroth, Germany). Routine clin-
ical variables were determined using established routine protocols.
For protein microarray experiments, serum was prepared in
accordance with the manufacturer’s protocol (Kabe Laborstechnik
GmbH). The sera were stored in small aliquots at 280uC until
transport and analysis in Germany.
Protein Microarray
Before performing the protein microarray, the slides (Proto-
Array, Life Technologies, Carlsbad, USA) were equilibrated at
4uC for 15 min and then for an additional 15 min at room
temperature. Only 10 mL of serum was used for each protein
microarray experiment. Blocking, serum incubation, and washing
steps were carried out as described in the manufacturer’s protocol
(Life Technologies), with the exception that an automatic slide
washer (M2-Automation, Berlin, Germany) was used. Image
acquisition of the processed protein microarrays was performed
with an Array-Scanner FR202 using CCD Technology (Strix
Diagnostics GmbH, Berlin, Germany).
Raw Data Acquisition
The raw fluorescence intensity data were acquired using
StrixAluco 3 microarray image analysis software (Strix Diagnostics
GmbH, Berlin, Germany). For this purpose, the lot-specific GAL
file (GenePixH Array List file, obtained from Life Technologies’
ProtoArray web site http://www.lifetechnologies.com) was im-
ported into the software, and all microarray image files were
processed automatically in batch format using the StrixAluco
batch mode. This resulted in a set of 40 GPR files (GenePixH
Results, 1 file for each microarray) containing all of the raw
intensity data.
Selection of Highly Immunoreactive IgG Antibodies
Directed against Human Proteins
The method used in this study was an adaption of the approach
proposed by Jiang et al. [17]. For statistical analysis, the acquired
raw data were imported into R (http://www.r-project.org/, [18])
via the Bioconductor (http://www.bioconductor.org/, [19]) pack-
age limma [20]. After joint preprocessing (the preprocessed data
are available at www.medizinisches-proteom-center.de/May_et_
al), approximately one-third of the microarrays (6 ALS vs. 6
NDCs) were randomly selected as the test set, and the remainder
(14 ALS vs. 14 NDCs) were used as the training set. The following
selection procedure (‘‘feature selection’’) was applied to the
training set only: for each protein feature, a ‘‘minimum M-
Statistic’’ p value (‘‘M Score’’ [21–23]) was computed. All of the
protein features were then sorted by means of their M Score values
in order to pre-select the 300 proteins with the lowest (i.e., best) M
Scores (corresponding average M Score cut-off: 0.004566). The set
of proteins resulting from this univariate preselection was
narrowed down by multivariate selection using a random forest
(RF) classifier wrapped with a backward elimination approach
(‘‘gene shaving’’ (GS), [17,24,25]). Subsequently, the selected
features were verified using the test set for classification accuracy
estimation. The whole procedure, including the training/test set
sampling, univariate/multivariate selection, and verification, was
repeated 100 times (100 ‘‘subruns’’). The 20 most frequently
obtained features were then finally selected (‘‘frequency of
selections’’-based approach [26]). As verification of this candidate
biomarker panel, 100 RF classifications using 100 redrawn
training and test set splits were performed. Additionally, the final
selected set of highly immunoreactive antibodies was re-verified
using an alternative data analysis approach (Prediction Analysis of
Microarrays, PAM [27,28]); refer to the Supporting Information
for a detailed description of these methods.
Results
Characteristics of the Study Groups
Details about the study groups are provided in Table 1. The
median age of the cases and controls was 60 years, 50% were
Identification of Autoantibodies in ALS Patients
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female, and 55% of both groups had never smoked. The average
ALSFRS was 39 (range 16–46). The median time since ALS
diagnosis in the ALS cases was 18 months (range 2–60). None of
the ALS patients exhibited severe signs of cognitive impairment
(median MMS 29.5).
Routine laboratory variables are listed in Table 2. The ALS
cases demonstrated significantly higher levels of cholesterol,
creatine kinase, gamma globulin, glutamate-oxaloacetate amino-
transferase, and glutamate-pyruvate aminotransferase. The medi-
an concentrations of cholesterol and creatine kinase among the
cases were higher than the cut-offs for the normal range. However,
no differences in total immunoglobulins E, A, G, or M could be
detected between cases and controls.
Differences in the Immunoreactivity of IgG Antibodies
Differences in the immunoreactivity of IgG antibodies directed
against human proteins were analyzed in the sera of 20 ALS
patients relative to 20 controls. The serum from each individual in
each group was probed using protein microarrays containing
9,480 different human proteins. Large numbers of immunoreac-
tive antibodies were detected in both groups; therefore, and
multistep statistical analysis was carried out in an attempt to
identify high-level antibodies discriminating the study groups.
We performed a statistical selection for discriminating the
antibodies, as previously described. In each of the 100 subruns, 1
set of features was selected. The respective test set classification
accuracy for these 100 feature panels ranged from 54.8% to 100%,
with an average accuracy of 85.6%. Altogether, 207 features were
selected at least once. The frequencies of the 20 most frequent
protein features for all subruns are presented in Table 3. The most
frequent protein was RAB 13, which was selected in 36% of all
sub-runs. The next most frequent proteins were Syntaxin 11 and
ribosomal protein S6 kinase, which were selected in 28% and 26%
of the subruns, respectively. The least frequently selected protein
was the BTB/POZ domain-containing protein, which was selected
in 10% of all the subruns, the threshold set for the final potential
biomarker candidates in this study. Among all 100 subruns, the
most similar subrun panel comparing these 20 features contained
12 of these features and 19 additional proteins. For the
corresponding subrun test set, the classification accuracy was
97.7%. The p values (see Table 3) of the 20 best-discriminating
candidate proteins were ,0.05 after adjustment for multiple
testing using the method of Benjamini-Hochberg (FDR). The
verification experiment to show that these 20 antibodies were
discriminative as a panel for our microarray data set (100 RF
classifications using 100 redrawn training and test set splits) yielded
an average classification accuracy of 99.9% and an average
sensitivity of 99.9%, and the corresponding specificities always
proved to be 100%. Moreover, the fluorescence intensities of the
20 antibodies displayed a clear trend towards differentiating
between ALS and control samples (Figure 1). As shown in Table 3,
14 of the 20 selected antibodies were also selected by PAM (i.e.,
position #245 of 9,480 in the ranked feature list obtained from
PAM analysis), and 2 additional proteins were close to this
selection level (positions 269 and 290).
Clinical Data from the Patients with Lower and Higher
Antibody Levels Directed Against the 20 Selected
Proteins
The sera from 5 of the 20 ALS patients contained particularly
high levels of immunoreactive IgG antibodies directed against the
20 selected proteins. Therefore, we compared the clinical data
from this subgroup with the data from the remaining 15 ALS
patients with lower reactivities (Table 4). However, the immuno-
reactivities of the sera from the 15 remaining patients were still
higher than the reactivities of the sera from the control group.
The age of the ALS patients with lower levels of detected IgG
antibodies was on average 59 years (median: 59, range 44–75)
compared with 52 years for patients with higher immunoreactivities:
(median: 52, range 47–61). The duration of the disease at the time of
obtaining the blood samples in patients with lower immune
reactivities was shorter (median: 12 months, range 2–60) compared
to patients with higher immunoreactivities (median: 24 months,
range 18–36). The ALSFRS for the patients with lower immune
reactivities indicated a less severe disease stage (median: 40, range
17–46) than for patients with higher immune reactivities (median:
32, range 16–40). The typical disease symptoms and signs in the
group with the higher immunoreactivities appeared earlier, and
their disease was more severe with more functional deficits. The
majority of the patients with higher immune reactivities demon-
strated bulbar symptoms (4 out of 5), as compared 7 out of 15 of the
patients with lower immune reactivities (Table 4).
Table 1. Characteristics of the study population (n = 40).
Total ALS patients Non-diseased controls
N %/Median (IQR1) N %/Median (IQR) N %/Median (IQR)
Gender Male 20 50% 10 50% 10 50%
Female 20 50% 10 50% 10 50%
Smoking status Never 22 55% 11 55% 11 55%
Former 12 30% 6 30% 6 30%
Current 6 15% 3 15% 3 15%
Education Low 2 5% 0 0% 2 10%
Medium 13 32.5% 9 45% 4 20%
High 25 62.5% 11 55% 14 70%
Age (median, range) 40 60 (43; 77) 20 60 (44; 77) 20 60 (43; 76)
Body-mass index [kg/m2] 40 27.0 (22.9; 29.7) 20 26.5 (20.5; 27.8) 20 28.0 (24.0; 32.0)
Mini-Mental score (max = 30) 14 29.5 (28; 30) – –
1Interquartile range.
doi:10.1371/journal.pone.0089596.t001
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Discussion
Inflammatory Mechanisms in ALS
The pathological hallmark of ALS is the degeneration of motor
neurons in the spinal cord, brain stem, and motor cortex, although
the cause of this degeneration currently remains unknown.
Moreover, the brain is not accessible for the early detection of
neurodegenerative diseases, and early clinical signs of motor
function impairment may be associated with misclassification of
this disease. Diagnostic serum markers are of special interest in
supporting the early detection of this fatal disease. Here, we
explored a large set of immunological serum markers to determine
Table 2. Blood analysis of the study groups presented as the median and interquartile range (IQR).
Standard
value Total
ALS
patients
Non-
diseased
controls
N Median IQR1 N Median IQR N Median IQR p value2
Alpha amylase [U/L] ,100 40 72 55.5 84.0 20 67.5 51.5 83 20 74 60.5 85.5 0.26
Albumin [g/L] 36–52 40 43.0 38.0 47.1 20 45.3 39.8 48.3 20 41.0 36.5 45.0 0.02
Alkaline phosphatase [U/L] ,129 40 78.0 68.0 87.0 20 76.0 62.0 84.5 20 81.5 74.5 91.0 0.16
Bilirubin [mmol/L] ,21 40 16.2 12.6 18.1 20 16.6 13.7 18.8 20 15.5 11.2 18.0 0.30
Calcium [mmol/L] 2.1–2.42 40 2.27 2.17 2.37 20 2.27 2.19 2.35 20 2.25 2.15 2.40 0.76
Cholesterol [mmol/L] ,5.2 40 5.23 4.77 5.67 20 5.62 5.23 5.88 20 4.82 4.43 5.20 ,0.0001
Creatine kinase [U/L] ,175 40 145 114 180 20 180 151.5 272 20 122 90.5 140.5 ,0.0001
Creatinine [mmol/L] 71–115 40 88.5 73.5 98.5 20 92.0 71.5 103.5 20 86.0 76.0 97.0 0.63
C-reactive protein [mg/L] ,5 40 3.20 2.25 4.00 20 3.50 2.85 4.30 20 2.95 2.15 3.60 0.14
Serum iron [mmol/L] 10.6–28.3 40 21.4 15.2 24.6 20 20.5 13.7 24.4 20 22.0 15.8 25.0 0.45
Gamma globulin [%] 6.2–15.4 40 12.8 10.2 14.4 20 14.1 12.4 14.5 20 11.5 9.8 13.1 0.01
Gamma-glutamyl
transpeptidase [U/L]
,50 40 22.5 16.5 28.0 20 18.0 17.0 28.0 20 23.5 15.5 28.5 0.94
Blood sugar [mmol/L] 3.3–5.6 40 5.36 4.90 5.60 20 5.55 4.95 5.80 20 5.20 4.90 5.5 0.09
Glutamate-oxaloacetate
aminotransferase [U/L]
,37 40 25.5 21.0 29.0 20 28.0 21.5 33.5 20 24.5 21.0 26.0 0.06
Glutamate-pyruvate
aminotransferase [U/L]
,40 40 26 22.0 31.0 20 30.0 24.0 34.0 20 23.5 21.0 28.0 0.04
Hemoglobin [g/dL] 133–167 40 14.8 14.1 15.2 20 14.5 13.9 15.1 20 15.0 14.5 15.3 0.07
High-density cholesterol
[mmol/L]
.1.0 40 1.28 1.15 1.46 20 1.22 1.11 1.47 20 1.35 1.23 1.5 0.19
Hematocrit [L/L] 0.39–0.55 40 0.48 0.44 0.51 20 0.45 0.42 0.51 20 0.49 0.45 0.51 0.22
Low-density cholesterol
[mmol/L]
,3 40 3.03 2.88 3.3 20 3.18 2.87 3.45 20 2.99 2.88 3.1 0.30
Parathormone [pmol/L] 1.6–6.9 40 4.05 2.80 5.1 20 3.58 2.8 5.1 20 4.39 2.93 5.0 0.74
Triglycerides [mmol/L] ,1.7 40 1.64 1.45 1.89 20 1.75 1.42 2.21 20 1.6 1.45 1.69 0.12
Thyroid-stimulating hormone
[mIU/L]
0.27–4.2 40 3.01 2.43 3.75 20 3.10 2.45 3.60 20 2.87 2.20 3.83 0.87
Carbamide nitrogen [mmol/L] 2.9–11.1 40 6.9 5.7 8.45 20 7.05 6 8.35 20 6.75 5.55 8.60 0.60
Uric acid [mmol/L] 200–416 40 315.5 245 346.5 20 326.5 270.5 373 20 284 229 331 0.12
White blood cell count [g/L] 3.7–9.5 40 7.65 6.4 8.8 20 7.23 6.05 8.7 20 7.82 6.74 8.95 0.19
Red blood cell sedimentation
rate [mm/h]
1–12 40 8.0 5.5 10.0 20 8.0 5.5 10.0 20 8.0 5.5 10.5 0.98
Immunoglobulin E [IU/L] ,100 40 38.2 17.0 87.5 20 30.1 16.3 71.7 20 52.2 18.6 95.5 0.48
Immunoglobulin A [g/L] 0.85–4.5
(male),
1.0–4.8
(female)
40 1.87 1.52 2.47 20 1.94 1.54 2.20 20 1.81 1.45 2.53 0.84
Immunoglobulin G [g/L] 8.0–17 40 9.52 8.51 10.85 20 9.27 8.51 10.54 20 9.83 8.84 11.32 0.22
Immunoglobulin M [g/L] 0.6–3.7
(male),
0.5–3.2
(female)
40 1.05 0.77 1.39 20 1.08 0.75 1.69 20 0.97 0.78 1.27 0.47
1Interquartile range,
2Kruskal-Wallis test.
doi:10.1371/journal.pone.0089596.t002
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their performance in discriminating ALS patients from non-
diseased subjects. We identified 20 candidate proteins that could
differentiate between the study groups with 100% specificity and
99.9% sensitivity. Various biostatistical methods were developed
and employed to control for overfitting [16,22–24]. Notably, total
immunoglobulin levels assessed using routine laboratory variables
were not different between cases and controls.
Our results are in agreement with the current knowledge of the
role of the immune system in ALS. A site-specific local
inflammatory reaction was demonstrated in the regions of motor
neuron degeneration both in ALS and in the SOD-1 transgenic
mouse model [29,30]. The main features of this inflammatory
reaction were the accumulation of IgG in the cytoplasm of the
motor neurons [29], the appearance of T cells [30] and antigen-
presenting dendritic cells, an alteration in the cytokine profile in
the affected tissue, and the activation of microglial cells and
astrocytes [31–34]. The cellular and biochemical evidence of
neuroinflammation in ALS patients and in animal models and the
evidence of the role of neuroinflammation in initiating and
amplifying the disease process and participating in the repair and
protective processes were reviewed by Simpson et al. [33].
In the last 25 years, experimental autoimmune motor neuron
diseases have been induced through the immunization of guinea
pigs and goats with purified IgG from ALS patients [35]. When
normal mice or guinea pigs are immunized with this IgG, the
clinical ALS signs and similar ultrastructural alterations as those
seen in humans with ALS can be observed [35].
In view of the wide spectrum of effects of anti-motor neuron
IgG from ALS patients in animal models, a set of antibodies may
hold promise as a biomarker panel for the early detection of ALS
and possibly for monitoring disease progression. Our approach
made use of the advantage of a high-density protein microarray
with extensive bioinformatic analysis to search for a set of high-
level antibodies as markers differentiating 20 ALS patients from 20
healthy subjects. The details of our bioinformatics tools have been
published elsewhere [17,24–26].
Figure 1. Fluorescence intensities of the antibodies bound to the selected 20 human proteins. Differential microarray fluorescence
intensities (y-axes, log scale) of 20 antibodies bound to the selected proteins (identified by their respective gene names). ALS patient sera are shown
in red (n = 20), and the control (NDC) sera are shown in blue (n = 20). The 40 samples (x-axes) were not paired. The samples were sorted by their
sample labels only (ALS1, ALS2, …, ALS20, NDC1, NDC2, …, NDC20). Differences in these values indicate different reactivities of the IgG from the
corresponding sera with the selected proteins.
doi:10.1371/journal.pone.0089596.g001
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Critical Points - Study Design and Antibodies as Potential
Biomarkers
To the best of our knowledge, this was the first study to evaluate
the humoral immune response in the form of IgG autoantibodies
for ALS profiling. In our study, the patient groups each consisted
of 20 subjects, with the controls matched to the cases based on age
and gender. Matching by age is important because the number of
antibodies directed against self-antigens increases with age.
Subjects taking immune-modulating drugs were excluded, and
the serum preparations for cases and controls were performed in
parallel and in a blinded manner according to a standardized
protocol. This approach was critical to avoid batch problems and
other forms of bias in the detection of disease-related antibodies
[27,28].
The Selection of Potential Biomarker Candidates
Our results demonstrated that the 20 ALS patients included in
this study could be distinguished from the controls through the use
of a small panel of 20 highly immunoreactive IgGs directed against
20 selected human proteins. The approach of repeated resampling
and the frequency of the selections led to the acquisition of the
most reproducible set of candidate markers for our dataset. The
robustness of these markers to serve as diagnostic markers was re-
verified independently using an alternative feature selection
strategy involving the use of PAM. Finally, the average classifi-
cation accuracy of 99.9% (based on 100 repeatedly resampled
test/training sets and the 20 markers) verified that the panel was
highly discriminatory for our data set. Nevertheless, our results
should be regarded as preliminary, and studies with more ALS
patients and controls and prospective studies with asymptomatic
subjects at baseline are needed to validate these candidate
biomarkers. Although we excluded patients taking immunother-
apies, many ALS patients receive different medications and have
elevated liver enzymes. Moreover, cross-sectional studies have
methodological shortcomings for biomarker research [36], and
prospective studies require international networks to gain sufficient
power in biomarker studies for the early detection of rare diseases
like ALS.
Levels of Antibodies in ALS Patients
The high level of antibodies directed against the 20 selected
human proteins appeared to be characteristic of the group of our
ALS patients, as these antibodies were not found to be elevated in
the age- and gender-matched controls. This antibody production
may be a consequence of the immune response to proteins
released from dying motor neurons. Because ALS involves a long
preclinical phase in which motor neurons are subject to decay, the
appearance of high-level antibodies directed against the 20
selected human proteins may predict the development of the
disease. Indeed, patients with higher antibody levels presented
with more severe symptoms as compared to patients with lower
antibody levels. The patients with high antibody levels were also
more prone to exhibit bulbar symptoms. This finding may be due
to a longer time between diagnosis and the measurement of the
antibody levels, which was on average 12 months later than in
patients with lower antibody levels. These findings may suggest
that increasing autoantibody levels could be used to track the
progression of ALS disease, and future longitudinal studies in ALS
patients could confirm this observation.
The Potential Role of Antibodies in ALS
It should be noted that we have no clear-cut evidence that any
or all of the 20 identified autoantibodies are pathogenic in ALS.
Nevertheless, there are several examples in which pathogenic
antibodies are generated alongside nonpathogenic antibodies in
patients with different diseases. The best such example is systemic
lupus erythematosus, although multiple pathogenic antibodies can
also be a feature of myasthenia gravis, in which antibodies directed
against different antigens of the neuromuscular junction are found
simultaneously with antibodies directed against different antigens
of the thyroid glands or mucous membrane of the stomach. The
20 identified proteins in our study have nothing in common with
known proteins involved in ALS inflammation; however, the
proteins identified in the present study are mostly intracellular,
intra-motor neuron proteins, indicating that the target of the
humoral immune response may be the motor neuron itself.
We could not confirm previous reports that identified antibodies
with alternative molecular targets such as neurofilaments, Fas
(CD95), fetal muscular proteins, vascular antigens, matrix
metalloproteinases, and calcium channel proteins, as reviewed
by Pagani et al., with the exception of mucolipin3 [6]. Neverthe-
less, it is noteworthy that the intracellular locations of the proteins
selected in this study are largely confined to those subcellular
organelles to which IgG binds intracellularly in ALS motor
neurons [34] and in mice injected with IgG from ALS patients [5].
Furthermore, such inoculated mice exhibited electrophysiological
and morphological alterations that were similar to those observed
in ALS patients.
The Sites and Normal Functions of the Selected Proteins
RAB 13 regulates endocytosis, membrane trafficking between
the trans-Golgi network and recycling endosomes, and neurite
outgrowth and regeneration [37,38]. Early endosomal membrane
compartments are required for the formation and recycling of
synaptic vesicles, and fragmentation of the Golgi apparatus is an
early event in the pathogenesis of neuronal degeneration in ALS.
However, the nature of the involvement of the Golgi in the
Table 4. Data on the patients with lower and higher levels of detected potential biomarker antibodies.
All ALS patients; N = 20 Low immunoreactivity; N = 15 High immunoreactivity; N = 5
Age (median, range) 59, 44–75 59, 44–75 52, 47–61
Female gender (N, %) 10, 50% 8, 53% 2, 40%
ALSFRS1 (median, range) 39, 16–46 40, 17–46 32, 16–40
Months between diagnosis and
blood analysis (median, range)
15, 2–60 12, 2–60 24, 18–36
Bulbar signs (N, %) 11, 55% 7, 46% 4, 80%
1Amyotrophic Lateral Sclerosis Functional Rating Scale.
doi:10.1371/journal.pone.0089596.t004
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pathogenic mechanism of neurodegenerative disease remains
unknown [39]. Furthermore, the following 3 selected proteins
are also localized to the Golgi network.
Syntaxin 11 is associated with late endosomes and the trans-
Golgi network [40] and is localized to synaptic vesicles [41]. When
IgG from ALS patients is administered intraperitoneally to mice,
the IgG is taken up in the motor axon terminals, binds to synaptic
vesicles, increases the intra-terminal level of Ca(2+), and accumu-
lates in the Golgi, which is dilated and displays an elevated Ca(2+)
content [5,35].
The cysteine-rich hydrophobic domain 2 protein is also
localized to the trans-Golgi network [42]. In fact, the Golgi
network is injured in one of the familial forms of ALS. Optineurin,
which is mutated in ALS 12, is responsible for maintaining the
integrity of the Golgi network, and this protein also plays a role in
exocytosis by interacting with RAB proteins [43]. Moreover,
mutation of the Alsin gene in familial ALS 2 impairs endocytosis
[44].
The intraflagellar transport 57 homolog protein is part of
the motor for retrograde axonal transport, and abnormalities in
this system have been linked to ALS. Defects in dynein-mediated
axonal transport have also been shown in transgenic SOD1 mice,
which are one of the models of genetic ALS [45]. Dynein is the
motor for the movement along microtubules, and different
mutations in dynactin, which attaches microtubules to dynein,
increase susceptibility to ALS [46]. IgG has also been detected
bound to microtubules both in spinal motor neurons in SALS and
also in mice inoculated with IgG from ALS patients [5]. However,
whether this phenomenon is partially responsible for the slowed
retrograde axonal transport in motor neurons in SALS is currently
unknown.
The rough endoplasmic reticulum (RER) is another subcellular
structure that is heavily loaded with IgG in motor neurons in
human ALS patients and animal models [5,34]. IgG appears to be
bound both to the ribosomes and to the membranes of cisternae of
the RER. Furthermore, the RER is vacuolar, and its Ca(2+)
content is increased [35].
One of the selected proteins in the RER is the ribosomal
protein S6 kinase. This protein takes part in signal transduction
and is a substrate of a ubiquitous and versatile mediator of
extracellular signal-regulated kinase, which is activated by growth
factors, peptide hormones, and neurotransmitters [47].
Another selected protein localized to the RER is the ORM1-
like 1 protein, which may indirectly regulate endoplasmic
reticulum-mediated Ca(2+) signaling [48,49].
Structural alterations and dysfunction of the above-mentioned
intracellular structures have recently been discovered in distinct
genetic forms of ALS. If intracellular antibodies are bound to other
proteins in these structures, the functions of these structures may
also be altered.
Mucolipin 3 belongs in a family of ion channel proteins that
are expressed in endosomes and lysosomes. This protein is a novel
Ca(2+)-permeable channel that releases Ca(2+) from endosomes and
lysosomes. This protein additionally plays a role in the regulation
of cargo trafficking along the endosomal pathway [50]. When IgG
from the sera of ALS patients was injected in mice, this IgG bound
to and accumulated in the lysosomes and endosomes of the motor
neurons [5].
Cerebellin family members are known to act as transneuronal
regulators of synapse development and synaptic plasticity in
various brain regions. Decreased concentrations of cerebellin have
been observed in the brains of patients with olivopontocerebellar
atrophy and Shy-Drager syndrome, suggesting a role for cerebellin
in the pathology of these diseases [51]. In certain ALS patients,
ALS plus syndrome develops in the late stage of the disease and
includes certain signs of Parkinson’s disease. Neuropathological
data indicate that the cerebellum may also be involved in the
neurodegenerative process in ALS, although the symptoms and
signs of the severe motor neuron degeneration may conceal the
cerebellar dysfunction [52].
Serine/threonine-protein kinase NEK 11 is involved in
the genotoxic stress response and DNA repair [53]. None-SMC
element 4 homolog A, (the non-structural maintenance of
chromosomes element 4 homolog A) similarly takes part in DNA
repair [54].
Missense mutation of the alpha crystallin domain in the
small heat shock protein HSP22 causes motor neuron-specific
neurite degeneration and alpha-B crystallin accumulation in
ballooned neurons in neurodegenerative diseases [55,56].
Zeta-crystallin, a quinone oxidoreductase, is related to
Torpedo and the mammalian synaptic vesicle membrane protein
VAT-1. VAT-1 is a major protein of the synaptic vesicles from
Torpedo [57]. IgG from the sera of ALS patients is taken up in the
axon terminal of the motor neurons and binds to the synaptic
vesicles [5].
Platelet factor 4 variant 1 is a potent regulator of
endothelial cell biology that affects angiogenesis and vascular
diseases [58]. A loss-of-function mutation in the angiogenin gene,
another regulator of angiogenesis, has been described in ALS
patients [59]. The alterations to the blood-brain barrier in ALS
were recently extensively reviewed [60]. ALS IgG administered
into mice was observed by electron microscopy and immunohis-
tochemistry to be bound to the surface of the endothelial cells and
transported in multivesicular bodies inside of the cells [5].
The BTB/POZ domain-containing protein is a protein
containing a common structural domain. Proteins that interact
with the BTB/POZ domain inhibit the death of motor neurons in
SOD mutant transgenic mice [61].
Thyroid hormone receptor alpha is a nuclear protein that
binds triiodothyronine. Autoimmune thyroid diseases have been
found to complicate ALS [62].
Conclusions
A panel of highly expressed IgG antibodies obtained from
serum samples was found to differentiate ALS patients from
controls with high specificity and sensitivity, and increasing disease
severity was associated with higher antibody levels in ALS cases.
Therefore, this panel may be of value as a potential biomarker to
use in diagnostics and in the monitoring the ALS disease
progression. However, validation of the prognostic features of
these candidate biomarkers in a prospective study with ALS
patients is important. Prospective studies on the diagnostic features
of these biomarkers should take into account the rare nature of
ALS, which results in low positive predictive values for diagnostic
tests. The application of a fluidic microarray platform is also an
important issue for future research.
Data Availability
The data are available at www.medizinisches-proteom-center.
de/May_et_al.
Supporting Information
Figure S1 Data analysis workflow. The main data analysis
workflow is outlined (without re-verification using PAM). The
automatic biomarker selection (‘‘feature selection’’, dashed box on
the left) was composed from 100 iterative subruns. In each subrun,
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the following 5 steps were performed: (1) random drawing of the
new test (6 ALS and 6 NDC samples) and new training sets (14
ALS and 14 NDC samples); (2) preselection of the 300 best
features with regard to M Scores from this training set
(corresponding average M Score cut-off: 0.004566); (3) further
narrowing by gene shaving (GS) using only the training set drawn
in (1); (4) use of the resulting features (‘‘subrun selection’’) to train a
random forest classifier (RF, using only the training set drawn in
(1); and (5) use of this classifier to predict the test set drawn in step
(1) to verify the subrun selection. These 100 subruns resulted in
100 distinct feature sets (i.e., subrun selections) selected from their
subrun-specific training set consisting of 1 to 45 proteins and
verified by prediction of their subrun-specific test set (average
accuracy: 85.6%). The occurrence of each feature in such a subrun
selection was next counted for a feature ranking concerning the
overall selection frequency. All subrun-selected features with a
frequency of at least 10% were reported in the final set of proteins
(20 features). Finally, these features were verified by RF training
and classification (test and training set redrawn from all samples,
100 times repeated) with an average accuracy of 99.9% and re-
verified by PAM analysis (not shown in this Figure).
(TIF)
Figure S2 Technical replicates. Quantile plots (log data) of the
worst (r = 0.9688) and best (r = 0.9914) pairs out of 12 pairs of
technical replicates analyzed in a preliminary study are shown.
(TIFF)
Figure S3 Heat map of the immunoreactivities of the antibodies
from the sera of ALS patients and NDCs. This heat map shows the
microarray fluorescence intensities (log scale) of the IgGs from the
20 ALS patients and 20 non-diseased controls bound to the
selected 20 proteins (identified by their respective gene names).
The ALS sera (n = 20, on the right) and non-diseased control sera
(n = 20, on the left) are shown in heat color representation
(red = low values, white/yellow = high values). The fluorescence
values of all antibodies were higher in total in the ALS group
compared to the non-diseased control group, suggesting higher
immune reactivity.
(TIFF)
File S1 Supporting information. Table S1, Results of a technical
replicates study. The results of a preliminary study with technical
replicates (8 microarrays, two different serum samples, two
different ProtoArray production lots) are shown. For all pairs of
technical replicates Pearson’s correlation coefficient (for log data)
and the average coefficient of variation (CV, for raw data) have
been computed. Due to batch effects the intra-lot reproducibility
(r = 0.9883, average CV = 9.01%) is better than the inter-lot
reproducibility (r = 0.9729, average CV = 11.61%) and the overall
reproducibility (r = 0.9780, CV = 10.74%).
(DOCX)
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